Menu

Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
📰

Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

US Top News and Analysis·14 days ago
#EHSokIIr
#cnbc#business#moderna#quarter#revenue
Long article (504 words) — no AI summary yet.
Reading 0:00
15s threshold

Moderna on Friday smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth, as some of its newer products gain momentum and Covid vaccine revenue outperforms.

Shares of Moderna rose roughly 3% in premarket trading on Friday.

The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.

"The new product and the diversification of geography is what has led to such a strong Q3," Moderna CEO Stéphane Bancel said in an interview ahead of the results.

The Moderna facility in Laval, Quebec, Canada, Sept. 19, 2025.

Graham Hughes | Bloomberg | Getty Images

For example, he said the company is seeing the "full-year impact" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.